<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Genome-wide integration site detection using Cas9 enriched amplification-free long-range sequencing]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765907386945-fba3e2c5-9e50-4db2-9344-71b03c9ca125/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1152</link>
            <description><![CDATA[<p class="para" id="N65541">The gene and cell therapy fields are advancing rapidly, with a potential to treat and cure a wide range of diseases, and lentivirus-based gene transfer agents are the vector of choice for many investigators. Early cases of insertional mutagenesis caused by gammaretroviral vectors highlighted that integration site (IS) analysis was a major safety and quality control checkpoint for lentiviral applications. The methods established to detect lentiviral integrations using next-generation sequencing (NGS) are limited by short read length, inadvertent PCR bias, low yield, or lengthy protocols. Here, we describe a new method to sequence IS using Amplification-free Integration Site sequencing (AFIS-Seq). AFIS-Seq is based on amplification-free, Cas9-mediated enrichment of high-molecular-weight chromosomal DNA suitable for long-range Nanopore MinION sequencing. This accessible and low-cost approach generates long reads enabling IS mapping with high certainty within a single day. We demonstrate proof-of-concept by mapping IS of lentiviral vectors in a variety of cell models and report up to 1600-fold enrichment of the signal. This method can be further extended to sequencing of Cas9-mediated integration of genes and to in vivo analysis of IS. AFIS-Seq uses long-read sequencing to facilitate safety evaluation of preclinical lentiviral vector gene therapies by providing IS analysis with improved confidence.</p>]]></description>
            <pubDate><![CDATA[2020-12-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Decoding the epitranscriptional landscape from native RNA sequences]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765834540189-27a77f27-c16d-41c9-b1c9-c17828968f26/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa620</link>
            <description><![CDATA[<p class="para" id="N65541">Traditional epitranscriptomics relies on capturing a single RNA modification by antibody or chemical treatment, combined with short-read sequencing to identify its transcriptomic location. This approach is labor-intensive and may introduce experimental artifacts. Direct sequencing of native RNA using Oxford Nanopore Technologies (ONT) can allow for directly detecting the RNA base modifications, although these modifications might appear as sequencing errors. The percent Error of Specific Bases (%ESB) was higher for native RNA than unmodified RNA, which enabled the detection of ribonucleotide modification sites. Based on the %ESB differences, we developed a bioinformatic tool, epitranscriptional landscape inferring from glitches of ONT signals (ELIGOS), that is based on various types of synthetic modified RNA and applied to rRNA and mRNA. ELIGOS is able to accurately predict known classes of RNA methylation sites (AUC &gt; 0.93) in rRNAs from <i>Escherichia</i><i>coli</i>, yeast, and human cells, using either unmodified <i>in vitro</i> transcription RNA or a background error model, which mimics the systematic error of direct RNA sequencing as the reference. The well-known DRACH/RRACH motif was localized and identified, consistent with previous studies, using differential analysis of ELIGOS to study the impact of RNA m<sup>6</sup>A methyltransferase by comparing wild type and knockouts in yeast and mouse cells. Lastly, the DRACH motif could also be identified in the mRNA of three human cell lines. The mRNA modification identified by ELIGOS is at the level of individual base resolution. In summary, we have developed a bioinformatic software package to uncover native RNA modifications.</p>]]></description>
            <pubDate><![CDATA[2020-07-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[CoolMPS: evaluation of antibody labeling based massively parallel non-coding RNA sequencing]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823386294-f90662b6-8f89-401e-8226-891cc25ba674/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1122</link>
            <description><![CDATA[<p class="para" id="N65541">Results of massive parallel sequencing-by-synthesis vary depending on the sequencing approach. CoolMPS™ is a new sequencing chemistry that incorporates bases by labeled antibodies. To evaluate the performance, we sequenced 240 human non-coding RNA samples (dementia patients and controls) with and without CoolMPS. The Q30 value as indicator of the per base sequencing quality increased from 91.8 to 94%. The higher quality was reached across the whole read length. Likewise, the percentage of reads mapping to the human genome increased from 84.9 to 86.2%. For both technologies, we computed similar distributions between different RNA classes (miRNA, piRNA, tRNA, snoRNA and yRNA) and within the classes. While standard sequencing-by-synthesis allowed to recover more annotated miRNAs, CoolMPS yielded more novel miRNAs. The correlation between the two methods was 0.97. Evaluating the diagnostic performance, we observed lower minimal <i>P</i>-values for CoolMPS (adjusted <i>P</i>-value of 0.0006 versus 0.0004) and larger effect sizes (Cohen's d of 0.878 versus 0.9). Validating 19 miRNAs resulted in a correlation of 0.852 between CoolMPS and reverse transcriptase-quantitative polymerase chain reaction. Comparison to data generated with Illumina technology confirmed a known shift in the overall RNA composition. With CoolMPS we evaluated a novel sequencing-by-synthesis technology showing high performance for the analysis of non-coding RNAs.</p>]]></description>
            <pubDate><![CDATA[2020-12-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Molecular underpinnings of ssDNA specificity by Rep HUH-endonucleases and implications for HUH-tag multiplexing and engineering]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765822892231-db3a3c2f-6dac-44f5-be92-e6a40c36cae8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1248</link>
            <description><![CDATA[<p class="para" id="N65541">Replication initiator proteins (Reps) from the HUH-endonuclease superfamily process specific single-stranded DNA (ssDNA) sequences to initiate rolling circle/hairpin replication in viruses, such as crop ravaging geminiviruses and human disease causing parvoviruses. In biotechnology contexts, Reps are the basis for HUH-tag bioconjugation and a critical adeno-associated virus genome integration tool. We solved the first co-crystal structures of Reps complexed to ssDNA, revealing a key motif for conferring sequence specificity and for anchoring a bent DNA architecture. In combination, we developed a deep sequencing cleavage assay, termed HUH-seq, to interrogate subtleties in Rep specificity and demonstrate how differences can be exploited for multiplexed HUH-tagging. Together, our insights allowed engineering of only four amino acids in a Rep chimera to predictably alter sequence specificity. These results have important implications for modulating viral infections, developing Rep-based genomic integration tools, and enabling massively parallel HUH-tag barcoding and bioconjugation applications.</p>]]></description>
            <pubDate><![CDATA[2021-01-07T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[CoolMPS for robust sequencing of single-nuclear RNAs captured by droplet-based method]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765820665254-f23bf339-1624-447d-bf4d-67146ff45095/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1127</link>
            <description><![CDATA[<p class="para" id="N65541">Massively-parallel single-cell and single-nucleus RNA sequencing (scRNA-seq, snRNA-seq) requires extensive sequencing to achieve proper per-cell coverage, making sequencing resources and availability of sequencers critical factors for conducting deep transcriptional profiling. CoolMPS is a novel sequencing-by-synthesis approach that relies on nucleotide labeling by re-usable antibodies, but whether it is applicable to snRNA-seq has not been tested. Here, we use a low-cost and off-the-shelf protocol to chemically convert libraries generated with the widely-used Chromium 10X technology to be sequenceable with CoolMPS technology. To assess the quality and performance of converted libraries sequenced with CoolMPS, we generated a snRNA-seq dataset from the hippocampus of young and old mice. Native libraries were sequenced on an Illumina Novaseq and libraries that were converted to be compatible with CoolMPS were sequenced on a DNBSEQ-400RS. CoolMPS-derived data faithfully replicated key characteristics of the native library dataset, including correct estimation of ambient RNA-contamination, detection of captured cells, cell clustering results, spatial marker gene expression, inter- and intra-replicate differences and gene expression changes during aging. In conclusion, our results show that CoolMPS provides a viable alternative to standard sequencing of RNA from droplet-based libraries.</p>]]></description>
            <pubDate><![CDATA[2020-12-02T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Optimized design of antisense oligomers for targeted rRNA depletion]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765762240527-35880281-9301-4653-9572-8e301325617e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1072</link>
            <description><![CDATA[<p class="para" id="N65541">RNA sequencing (RNA-seq) is extensively used to quantify gene expression transcriptome-wide. Although often paired with polyadenylate (poly(A)) selection to enrich for messenger RNA (mRNA), many applications require alternate approaches to counteract the high proportion of ribosomal RNA (rRNA) in total RNA. Recently, digestion using RNaseH and antisense DNA oligomers tiling target rRNAs has emerged as an alternative to commercial rRNA depletion kits. Here, we present a streamlined, more economical RNaseH-mediated rRNA depletion with substantially lower up-front costs, using shorter antisense oligos only sparsely tiled along the target RNA in a 5-min digestion reaction. We introduce a novel Web tool, Oligo-ASST, that simplifies oligo design to target regions with optimal thermodynamic properties, and additionally can generate compact, common oligo pools that simultaneously target divergent RNAs, e.g. across different species. We demonstrate the efficacy of these strategies by generating rRNA-depletion oligos for <i>Xenopus laevis</i> and for zebrafish, which expresses two distinct versions of rRNAs during embryogenesis. The resulting RNA-seq libraries reduce rRNA to &lt;5% of aligned reads, on par with poly(A) selection, and also reveal expression of many non-adenylated RNA species. Oligo-ASST is freely available at https://mtleelab.pitt.edu/oligo to design antisense oligos for any taxon or to target any abundant RNA for depletion.</p><p class="para" id="N65542">
<div class="section" id="ga1"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('ga1');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765762240527-35880281-9301-4653-9572-8e301325617e/assets/gkaa1072gra1.jpg" alt="Oligo-ASST designs optimized antisense oligo sets to target RNAs for depletion."/></div></div><div class="imgeVideoCaption" id="N65544"><div class="captionTitle">Graphical Abstract</div><div class="captionText">                                      Oligo-ASST designs optimized antisense oligo sets to target RNAs for depletion.</div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-11-22T00:00]]></pubDate>
        </item>
    </channel>
</rss>